VEGFA and neoplasm: On the other hand, the increase in E2 and VEGF-A concentrations together after treatment with bevacizumab in both cell lines could correspond to the autocrine secretion of VEGF-A by E2-induced tumour cells [65], and to an extent, this VEGF-A could act as a survival factor for tumour cells to counteract the effect of bevacizumab.